1-7 of 7
Stefan Knackmuss
Close
Sort by
Journal Articles

AFM28, a Novel Bispecific Innate Cell Engager (ICE ® ), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Jana-Julia Götz, Jens Pahl, Nanni Schmitt, Thomas Müller, Torsten Haneke, Izabela Kozlowska, Séverine Sarlang, Stefan Knackmuss, Eike Peters, Uwe Reusch, Thorsten Ross, Daniel Nowak, Wolf-Karsten Hofmann, Christian Merz
Journal: Blood
Blood (2021) 138 (Supplement 1): 3344.
https://doi.org/10.1182/blood-2021-152463
Published: 2021
Journal Articles

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Galina Salogub, MD PhD, Jiri Mayer, MD, Frantisek Folber, MD PhD, Sebastian Grosicki, MD PhD, Aleksander B Skotnicki, MD PhD, Anna Prochwicz, MD, Alexander Myasnikov, MD, Alexander Gural, MD, Oliver Schoenborn-Kellenberger, MSc, Charlie Brindley, PhD, Stefan Knackmuss, PhD, Sylvia Schwarz, PhD, Sandra Schmich, Cassandra Choe-Juliak, MD MS, Andras Strassz, MD, Leila Alland, MD, Michael Doubek, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3969.
https://doi.org/10.1182/blood-2018-99-118136
Published: 2018
Journal Articles

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Thorsten Ross, PhD, Uwe Reusch, PhD, Susanne Wingert, PhD, Torsten Haneke, PhD, Katja Klausz, PhD, Anna-Kathrin Otte, PhD, Natalie Schub, MD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Thomas Valerius, MD, Martin Gramatzki, MD, Matthias Peipp, PhD, Michael Tesar, PhD, Erich Rajkovic, PhD MBA, Martin Treder, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1927.
https://doi.org/10.1182/blood-2018-99-118970
Published: 2018
Journal Articles

AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma

Thorsten Gantke, PhD, Uwe Reusch, PhD, Christian Kellner, PhD, Katja Klausz, PhD, Torsten Haneke, PhD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Anne Kerber, MD, Matthias Peipp, PhD, Martin Treder, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3082.
https://doi.org/10.1182/blood.V130.Suppl_1.3082.3082
Published: 2017
Journal Articles

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Clinical Trials & Observations
Achim Rothe, Stephanie Sasse, Max S. Topp, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Georg Kuhnert, Joerg Kessler, Carolin Buerkle, Miroslav Ravic, Stefan Knackmuss, Jens-Peter Marschner, Elke Pogge von Strandmann, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2015) 125 (26): 4024–4031.
https://doi.org/10.1182/blood-2014-12-614636
Published: 2015
Journal Articles

A CD19/CD3 Bispecific Tandab, AFM11, Recruits T Cells To Potently and Safely Kill CD19 + Tumor Cells

Eugene Zhukovsky, PhD, Uwe Reusch, Carmen Burkhardt, Stefan Knackmuss, Ivica Fucek, Markus Eser, Fionnuala McAleese, Kristina Ellwanger, Melvyn Little, PhD
Journal: Blood
Blood (2013) 122 (21): 4405.
https://doi.org/10.1182/blood.V122.21.4405.4405
Published: 2013
Journal Articles

A T Cell-Engaging CD3 Recruit-Tandab Potently Kills CD19 + Tumor B Cells

Eugene Zhukovsky, PhD, Uwe Reusch, Carmen Burkhardt, Stefan Knackmuss, Ivica Fucek, Markus Eser, Fionnuala McAleese, Kristina Ellwanger
Journal: Blood
Blood (2012) 120 (21): 3721.
https://doi.org/10.1182/blood.V120.21.3721.3721
Published: 2012